Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498506 | 0.94 | HRH1 (0.63) | HRH1HRH3CYP1A2SMN1; SMN2CYP2C19 | |
| SCHEMBL7878429 | 0.92 | HRH1 (0.67) | HRH1HRH3CYP1A2SMN1; SMN2CYP2C19 | |
| SCHEMBL498601 | 0.92 | HRH1 (0.67) | HRH1HRH3CYP1A2SMN1; SMN2CYP2C19 | |
| SCHEMBL16288588 | 0.92 | HRH1 (0.67) | HRH1HRH3CYP1A2SMN1; SMN2CYP2C19 | |
| SCHEMBL2167104 | 0.92 | HRH1 (0.67) | HRH1HRH3CYP1A2SMN1; SMN2CYP2C19 | |
| SCHEMBL2167965 | 0.92 | HRH1 (0.67) | HRH1HRH3CYP1A2SMN1; SMN2CYP2C19 | |
| SCHEMBL8499503 | 0.92 | HRH1 (0.67) | HRH1HRH3CYP1A2SMN1; SMN2CYP2C19 | |
| SCHEMBL56199 | 0.86 | — | — | |
| SCHEMBL231470 | 0.86 | HRH1 (0.69) | HRH1HRH3CYP1A2SMN1; SMN2CYP2C19 | |
| SCHEMBL29485637 | 0.86 | HRH1 (0.69) | HRH1HRH3CYP1A2SMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 540 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253194-B2 | Compounds and inhibitors of phospholipases | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-08-07 | — | — | US | claimed |
| EP-1309552-A4 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | UNIV QUEENSLAND (AU) | 2005-07-20 | — | — | EP | claimed |
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | QUEENSLAND, THE UNIVERSITY OF (AU) | 2004-02-19 | — | — | US | claimed |
| JP-2004503604-A | — | — | 2004-02-05 | — | — | JP | claimed |
| EP-1309552-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2003-05-14 | — | — | EP | claimed |
| WO-2002008189-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2002-01-31 | — | — | WO | claimed |
| US-4839352-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1989-06-13 | — | — | US | claimed |
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-07-18 | — | — | US | disclosed |
| EP-4383238-A2 | IRIDIUM COMPLEX COMPOUND, COMPOSITION CONTAINING THE COMPOUND AND SOLVENT, ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THE COMPOUND, DISPLAY DEVICE, AND ILLUMINATION DEVICE | Mitsubishi Chemical Corporation (JP) | 2024-06-12 | — | — | EP | disclosed |
| EP-3719028-B1 | IRIDIUM COMPLEX COMPOUND, COMPOSITION CONTAINING SAID COMPOUND AND SOLVENT, ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING SAID COMPOUND, DISPLAY DEVICE AND ILLUMINATION DEVICE | MITSUBISHI CHEM CORP (JP) | 2024-06-12 | — | — | EP | disclosed |
| CN-113853381-B | Iridium complex compound, composition containing the compound and solvent, organic electroluminescent element containing the compound, display device and lighting device | 三菱化学株式会社 | 2024-06-11 | — | — | CN | disclosed |
| EP-4375280-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-05-29 | — | — | EP | disclosed |
| EP-4371985-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-05-22 | — | — | EP | disclosed |
| US-4172144-A | Schiff's base derivatives of thienamycin | MERCK & CO., INC. (US) | 1979-10-23 | — | — | US | disclosed |
| EP-0002210-A1 | 6- and 6,6- disubstituted-2-substituted-pen-2-em-3-carboxylic acids; processes for their preparation and pharmaceutical compositions containing such compounds | MERCK & CO. INC. (US) | 1979-06-13 | — | — | EP | disclosed |
| US-4150145-A | ANTIBIOTIC, BACTERICIDES | MERCK & CO., INC. (US) | 1979-04-17 | — | — | US | disclosed |
| EP-0001265-A1 | O-, N- and carboxyl derivatives of thienamycin sulfoxide and sulfone, their preparation and pharmaceuticals containing said compounds | MERCK & CO. INC. (US) | 1979-04-04 | — | — | EP | disclosed |
| EP-0001264-A1 | Substituted N-methylene derivatives of thienamycin sulfoxide and sulfone and their preparation | MERCK & CO. INC. (US) | 1979-04-04 | — | — | EP | disclosed |
| US-4120957-A | ANTHELMINTICS | ROHM AND HAAS COMPANY (US) | 1978-10-17 | — | — | US | disclosed |
| US-3953596-A | 8-Oxa-3-azabicyclo(3.2.1)octane analgesic compositions and method of alleviating pain in animals | ICI UNITED STATES INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | PLA2G4C, PLA2G4B, PLA2G4A | HRH1 1315/4885HRH3 1047/4885CYP1A2 2230/4885 |
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | CYP7A1, UGT1A3, UGT1A1 | HRH1 4219/4885HRH3 4614/4885CYP1A2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.